2-(4-Bromo-3,5-dimethoxyphenyl)-1,3-dioxolane | 123796-61-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-Bromo-3,5-dimethoxyphenyl)-1,3-dioxolane
• 英文别名: 4-bromo-3,5-dimethoxybenzaldehyde ethylene acetal
• CAS: 123796-61-2
• 化学式: C₁₁H₁₃BrO₄
• 分子量: 289.126
• InChiKey: IFHSHLZKBBYEOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  36.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-Bromo-3,5-dimethoxyphenyl)-1,3-dioxolane 在 sodium tetrahydroborate 、 正丁基锂 、 三丁基膦 、 偶氮二甲酰胺 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 二氯甲烷 、 苯 为溶剂， 反应 1.91h， 生成 2-[3,5-dimethoxy-4-(4-methoxyphenoxymethyl)phenyl][1,3]dioxolane
  参考文献：
  名称：

  A Self-Immolative Spacer That Enables Tunable Controlled Release of Phenols under Neutral Conditions

  摘要：

  A current challenge in the area of responsive materials is the design of reagents and polymers that provide controlled release of phenols in environments that are less polar than water. In these contexts, a molecular strategy that enables release of nearly any phenol with predictable and tunable rates and without complication from background hydrolysis would substantially increase the precision with which materials can be designed to respond to a particular signal. This Article addresses this problem at the fundamental level by describing the design, synthesis, and physical-organic characterization of two small molecule self-immolative spacers that are capable of releasing phenols in organic and mixed organic aqueous solutions. The rate of release from these small molecule model systems is predictable and tunable, such that nearly any type of phenol, regardless of pK(a) value, can be released in neutral solutions without complications from nonspecific background release due to hydrolysis. Furthermore, the release properties of the spacers can be predicted from bond length and conformation data (obtained from crystal structures). On the basis of these results, it should now be possible to incorporate these design elements into materials to enable precise response properties in environments that are not 100% aqueous.

  DOI：

  10.1021/jo300400q
• 作为产物：
  描述：

  4-溴-3,5-二甲氧基苯甲醛 在 p-TSA 作用下， 以 乙二醇 、 甲苯 为溶剂， 生成 2-(4-Bromo-3,5-dimethoxyphenyl)-1,3-dioxolane
  参考文献：
  名称：

  Inhibitors of &agr;4 mediated cell adhesion

  摘要：

  本发明涉及一种包含作为活性成分的化合物的药物组合物，其中环A是芳香族或杂环环；Q是键，羰基，低烷基，低烯基，—O-(低烷基)-等；n为0、1或2；Z为氧或硫，W为氧、硫、—CH═CH—、—NH—或—N═CH—；R1、R2和R3相同或不同，为氢、卤素、羟基、取代或未取代的低烷基、取代或未取代的低烷氧基、取代或未取代的氨基等；R4为四唑基、羧基、酰胺或酯基；R5为氢、硝基、氨基、羟基、低烷酰基、低烷基等；R6选自(a)取代或未取代的苯基、(b)取代或未取代的吡啶基、(c)取代或未取代的噻吩基、(d)取代或未取代的苯并呋喃基等；或其药学上可接受的盐。

  公开号：

  US06521666B1

文献信息

• Synthetic approaches to the naphthyl-isoquinoline alkaloids. Part 1. Dehydroancistrocladisine
  作者：Mark A. Rizzacasa、Melvyn V. Sargent

  DOI：10.1039/p19910000841

  日期：——

  A synthesis of (±)-7-(4,5-dimethoxy-2-methyl-1-naphthyl)-6,8-dimethoxy-1,3-dimethylisoquinoline (dehydroancistrocladisine)19, the racemic form of a degradation product of the unusual naphthylisoquinoline alkaloid ancistrocladisine 3, is recorded. The key step relied on oxazoline chemistry for the construction of the biaryl linkage.

  （±）-7-（4,5-二甲氧基-2-甲基-1-萘基）-6,8-二甲氧基-1,3-二甲基异喹啉（dehydroancistrocladisine）19的合成，其外消旋形式是其降解产物。记录到不寻常的萘基异喹啉生物碱顺氯二碱3。关键步骤依赖于恶唑啉化学方法来构建联芳基。
• Synthetic approaches to the alkaloids of the ancistrocladacea: dehydroancistrocladisine
  作者：Mark Rizzacasa、Melvyn V. Sargent

  DOI：10.1039/c39890000301

  日期：——

  Dehydroancistrocladisine, a derivative of ancistrocladisine which is a member of the unusual naphthyl-isoquinoline group of alkaloids, has been synthesized by a route which can be adapted to provide asymmetric syntheses of these alkaloids.

  脱氢脱水顺氯二十二胺是顺式二甲胺的衍生物，其是生物碱的不寻常的萘基-异喹啉基团的成员，其合成方法可用于提供这些生物碱的不对称合成。
• Synthesis of <i>C</i>-prenylated analogues of stilbenoid methyl ethers and their cyclic dihydrobenzopyranyl derivatives as potential anti-inflammatory agents
  作者：Hana Pizova、Milan Malanik、Karel Smejkal、Michal Oravec、Pavel Bobal

  DOI：10.1039/d2ra00441k

  日期：——

  An efficient and versatile synthesis of the naturally occurring C-prenylated stilbenoid methyl ethers and their synthetic analogues is presented. The synthesis represents a six step convergent process including an optimised C-prenylation method. Furthermore, during the demethylation process, six new dihydro-benzopyranyl derivatives were obtained and isolated.

  介绍了天然存在的C-异戊二烯化茋甲基醚及其合成类似物的有效且通用的合成方法。该合成代表了包括优化的C-异戊二烯化方法在内的六步收敛过程。此外，在去甲基化过程中，获得并分离了六种新的二氢苯并吡喃衍生物。
• [EN] INHIBITORS OF alpha 4 MEDIATED CELL ADHESION<br/>[FR] INHIBITEURS DE L'ADHESION CELLULAIRE A MEDIATION PAR alpha 4
  申请人：TANABE SEIYAKU CO., LTD.

  公开号：WO1999036393A1

  公开（公告）日：1999-07-22

  (EN) The present invention relates to a pharmaceutical composition comprising as an active ingredient a compound of formula (I), wherein Ring A is an aromatic or a heterocyclic ring; Q is a bond, carbonyl, lower alkylene, lower alkenylene, -O-(lower alkylene)-, etc.; n is 0, 1 or 2; Z is oxygen or sulfur; W is oxygen, sulfur, -CH=CH-, -NH- or -N=CH-; R1, R2 and R3 are the same or different and are hydrogen, halogen, hydroxyl, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted amino group, etc.; R4 is tetrazolyl, carboxyl group, amide or ester; R5 is hydrogen, nitro, amino, hydroxyl, lower alkanoyl, lower alkyl, etc.; R6 is selected from (a) a substituted or unsubstituted phenyl group, (b) a substituted or unsubstituted pyridyl group, (c) a substituted or unsubstituted thienyl group, (d) a substituted or unsubstituted benzofuranyl group, etc.; or a pharmaceutically acceptable salt thereof.(FR) L'invention se rapporte à une composition pharmaceutique comprenant en tant que composant actif le composé correspondant à la formule suivante: (1) dans laquelle Le cycle A est un cycle aromatique ou hétérocyclique; Q est une liaison carbonyle, alkylène inférieur, alcénylène inférieur, -O-(alkylène inférieur)-, etc.; n est 0, 1 ou 2; Z est oxygène ou soufre; W est oxygène, soufre, -CH=CH-, NH- ou -N=CH-; R1, R2 et R3 sont identiques ou différents et sont hydrogène, halogène, hydroxyle, groupe alkyle inférieur substitué ou non substitué, groupe alcoxy inférieur substitué ou non substitué, groupe amino substitué ou non substitué; R4 est tétrazolyle, groupe carboxyle, amide ou ester; R5 est hydrogène, nitro, amino, hydroxyle, alcanoyle inférieur, alkyle inférieur, etc.; R6 est sélectionné entre (a) un groupe phényle substitué ou non substitué, (b) un groupe pyridyle substitué ou non substitué, (c) un groupe thiényle substitué ou non substitué ou (d) un groupe benzofuranyle substitué ou non substitué, etc.; ou à un sel pharmaceutiquement acceptable de ce composé.

  本发明涉及一种药物组合物，其作为活性成分包含式（I）的化合物，其中环A是芳香环或杂环；Q是键，羰基，低碳基，低烯基，-O-（低碳基）-等；n为0，1或2；Z为氧或硫；W为氧，硫，-CH=CH-，-NH-或-N=CH-；R1，R2和R3相同或不同，是氢，卤素，羟基，取代或未取代的低碳基团，取代或未取代的低烷氧基团，取代或未取代的氨基团等；R4为四唑基，羧酸基，酰胺或酯；R5为氢，硝基，氨基，羟基，低烷酰基，低碳基等；R6从（a）取代或未取代的苯基团，（b）取代或未取代的吡啶基团，（c）取代或未取代的噻吩基团，（d）取代或未取代的苯并呋喃基团等中选择；或其药学上可接受的盐。
• Inhibitors of alpha4 mediated cell adhesion
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：US20030191118A1

  公开（公告）日：2003-10-09

  The present invention relates to a pharmaceutical composition comprising as an active ingredient a compound of formula (I), wherein Ring A is an aromatic or a heterocyclic ring; Q is a bond, carbonyl, lower alkylene, lower alkenylene, —O— -(lower alkylene)-, etc.; n is 0, 1 or 2; Z is oxygen or sulfur; W is oxygen, sulfur, —CH═CH—, —NH— or —N═CH—; R 1 , R 2 and R 3 are the same or different and are hydrogen, halogen, hydroxyl, a substituted or unsubstituted lower alkyl gorup, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted amino group, etc.; R 4 is tetrazolyl, carboxyl group, amide or ester; R 5 is hydrogen, nitro, amino, hydroxyl, lower alkanoyl, lower alkyl, etc.; R 6 is selected from (a) a substituted or unsubstituted phenyl group, (b) a substituted or unsubstituted pyridyl group, (c) a substituted or unsubstituted thienyl group, (d) a substituted or unsubstituted benzofuranyl group, etc.; or a pharmaceutically acceptable salt thereof.

  本发明涉及一种药物组合物，其包含化合物(I)作为活性成分，其中环A是芳香环或杂环；Q是键，羰基，低碳链，低烯链，-O-(低碳链)-等；n为0、1或2；Z为氧或硫；W为氧、硫、-CH═CH-、-NH-或-N═CH-；R1、R2和R3相同或不同，分别为氢、卤素、羟基、取代或未取代的低烷基、取代或未取代的低烷氧基、取代或未取代的氨基等；R4为四唑基、羧基、酰胺或酯基；R5为氢、硝基、氨基、羟基、低烷酰基、低烷基等；R6选自(a)取代或未取代的苯基、(b)取代或未取代的吡啶基、(c)取代或未取代的噻吩基、(d)取代或未取代的苯并呋喃基等；或其药学上可接受的盐。